Debt Financing
ABVC sells $4.1 million of discounted convertible notes for $3.39 million and pays Lind $625,000 to end lawsuit
The notes mature June 30, 2027 and convert at 85% of recent prices down to a $0.20 floor. ABVC had $31,944 in cash at June 30 and reports substantial doubt about its ability to continue as a going concern.

ABVC BioPharma, Inc. (Nasdaq: ABVC) sold senior convertible notes with $4,106,060 in principal for a purchase price of $3,387,500 on October 30, 2026, and will use part of the money to pay Lind Global Fund II, L.P. $625,000 to settle a lawsuit Lind filed in February. Chief Executive Officer Uttam Patil signed the 8-K. The notes carry a 17.5% original issue discount, convert at 85% of recent trading prices and mature on June 30, 2027. ABVC takes on this debt with very little cash. Its quarterly report showed $31,944 in cash and cash equivalents and a working capital deficit of $5,282,776 at June 30, 2026, and said its losses, deficit and cash outflows give rise to substantial doubt about its ability to continue as a going concern. 8-K Q2 10-Q
The note terms
The gap between principal and purchase price is $718,560. ABVC can extend maturity once by three months, which raises principal by 5%. Holders can convert only after the eight-month anniversary of issuance, and any conversion before the original maturity date needs the company's prior written consent. Eight months from October 30 is June 30, 2027, the maturity date, so without consent or the extension holders have little room to convert and ABVC faces about $4.1 million of principal due that day. The conversion price is 85% of the average of the three VWAPs for the three trading days before conversion, with a floor price of $0.20. Conversions are capped at 4.99% beneficial ownership (9.99% at the holder's election). 8-K
Under Nasdaq Listing Rule 5635(d), ABVC cannot issue conversion shares above 19.99% of the shares outstanding on the date of the purchase agreement without stockholder approval. It has agreed to seek that approval, and failing to get it by June 30, 2027 is an event of default. The company may prepay at 102.5% of principal, and it must prepay the lesser of 20% of the net proceeds of any later financing transaction and the outstanding principal. On default, holders can demand the Mandatory Default Amount or convert at the Alternate Conversion Price. For six months ABVC may not enter variable rate transactions other than an at-the-market offering and an acceptable equity line, and the buyers may take up to 100% of any subsequent financing. 8-K
Banks, advisors and fees
WallachBeth Capital acted as exclusive placement agent under an engagement letter dated October 5, 2026. The 8-K calls it WallachBeth Capital, LLC, and the press release calls it WallachBeth Capital, Inc. ABVC paid it a cash fee of 7% of gross proceeds, $237,125, and reimbursed $65,000 of accountable expenses. The release says Hunter Taubman Fischer & Li LLC acted as legal counsel to ABVC and Sichenzia Ross Ference Carmel LLP as counsel to the placement agent. After the agent's fee and expenses and the Lind payment, about $2.46 million of the $3,387,500 is left before other offering costs. 8-K Press release
The Lind settlement
Lind sued ABVC on February 13, 2026, in the Supreme Court of New York, New York County, in Lind Global Fund II L.P. v. ABVC Biopharma, Inc., Index No. 655319/2026. Lind's notes date back to a Senior Convertible Note dated November 17, 2023. Under a settlement agreement signed October 26, 2026, ABVC pays $625,000. Once Lind receives it, the Lind notes are deemed paid and cancelled, and the related liens, security interests and guarantees are released. After timely payment, Lind will file a stipulation of discontinuance with prejudice. 8-K
Its warrant to buy 398,000 shares at an original exercise price of $1.00 increases by 20%, and ABVC must register those shares within 90 days. Lind receives a 12-month right to take 10% to 25% of company or subsidiary cash financings, except deals in which a single investor puts in $2 million or more. Lind consented to the new notes and agreed to delete all prohibitions and consent requirements on variable rate transactions for this placement and for all future financings. In our reading, the settlement is what cleared the way for this note sale. 8-K
The business
ABVC describes itself as a clinical-stage biopharmaceutical company with six drugs in development for central nervous system disease and oncology, plus one device, ABV-1701/Vitargus, for ophthalmology. It runs proof-of-concept trials through Phase II with technology licensed from institutions including Stanford University, the University of California at San Francisco and Cedars-Sinai Medical Center. The release presents licensing revenues, milestone payments and royalties as opportunities and reports none received. Press release
ABVC reported a net loss of $2,500,418 for the first six months of 2026 and operating cash outflows of $1,138,656. Q2 10-Q At an October 28 special meeting, shareholders approved a 2026 Equity Incentive Plan and approved issuing up to 1,600,653 shares at not less than $1.00 a share for land in Taoyuan and real property in Hualien, Taiwan. 8-K
The next quarterly report should show how much cash was left after the Lind payment. The June 30, 2027 maturity and the stockholder vote on the 19.99% cap come next. 8-K
Investor Chat
Loading posts…
aibio